Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Ticker
CRL
Exchange
NYSE
Sector
Healthcare
Industry
Diagnostics & Research
Market cap
$15.95B
52-week range
$146.20 - $379.63

Valuation

Share price
$333.25 (close of Nov 18, 2026)
P/E (TTM)
314.39x
Price to book
4.94x
Price to free cash flow
39.92x
Enterprise value
$18.60B
Book value per share
$67.51

Price performance

PeriodChange
1 day+0.33%
5 days-2.75%
1 month+11.03%
3 months+19.36%
6 months+122.27%
Year to date+67.06%
1 year+105.04%
3 years+76.29%
5 years-14.00%
10 years+353.40%
All time+1,414.77%

Short interest

As of
Oct 30, 2026
Short % of float
7.20%
Shares short
2.99M
Days to cover
2.23
Change since prior report
+5.40%
Source
FINRA consolidated short interest

Members of Congress who disclosed CRL trades

Jefferson Shreve · Robert Bresnahan · Julie Johnson

Super investors holding CRL

Bill Nygren (Harris Associates LP) · John Rogers (Ariel Investments LLC) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates)

Profitability and growth

Return on equity
-4.55%
Return on invested capital
0.22%
Return on assets
-2.02%
Return on capital employed
0.42%
Gross margin
19.13%
Net margin
-3.59%
EBITDA margin
10.67%
Revenue growth
-0.85%
Free cash flow growth
3.37%

Cash flow and balance sheet

Free cash flow yield (TTM)
2.50%
Current ratio
1.41x
Net debt to EBITDA
9.00x

Latest reported year

Period end
Dec 27, 2025
Fiscal year
2025
Revenue
$4.02B
Cost of revenue
$3.25B
Gross profit
$768.24M
EBITDA
$428.47M
Net income
-$144.34M
Earnings per share
$-2.91
Interest expense
$107.03M
Shares outstanding
49.56M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-27$4.02B$768.24M-$144.34M-$2.91
2024-12-28$4.05B$978.35M$22.20M$0.20
2023-12-30$4.13B$1.37B$474.62M$9.27
2022-12-31$3.98B$1.32B$486.23M$9.57
2021-12-25$3.54B$1.21B$390.98M$7.77
2020-12-26$2.92B$961.66M$364.30M$7.35
2019-12-28$2.62B$868.77M$252.02M$5.17
2018-12-29$2.27B$775.24M$226.37M$4.72
2017-12-30$1.86B$659.55M$123.36M$2.60
2016-12-31$1.68B$602.26M$154.76M$3.29

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-2719.13%-3.59%-4.55%0.22%
2024-12-2824.16%0.55%0.64%2.58%
2023-12-3033.06%11.49%13.18%7.74%
2022-12-3133.10%12.23%16.31%8.56%
2021-12-2534.17%11.04%15.40%9.25%
2020-12-2632.89%12.46%17.20%8.21%
2019-12-2833.14%9.61%15.39%8.23%
2018-12-2934.21%9.99%17.15%8.97%
2017-12-3035.51%6.64%11.78%6.65%
2016-12-3135.82%9.20%18.44%8.32%

Cash and debt by year

Period endCashDebt
2025-12-27$213.77M$2.14B
2024-12-28$194.61M$2.24B
2023-12-30$276.77M$2.65B
2022-12-31$233.91M$2.71B
2021-12-25$242.28M$2.66B
2020-12-26$229.45M$1.93B
2019-12-28$238.96M$1.85B
2018-12-29$196.33M$1.63B
2017-12-30$192.28M$1.09B
2016-12-31$121.40M$1.19B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-27$518.49M$71.08M
2024-12-28$501.61M$69.89M
2023-12-30$365.37M$72.05M
2022-12-31$294.91M$73.62M
2021-12-25$532.03M$71.47M
2020-12-26$380.01M$56.34M
2019-12-28$340.42M$57.27M
2018-12-29$301.09M$47.35M
2017-12-30$235.64M$44.00M
2016-12-31$261.61M$43.64M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-04Sep 2026$2.98
2026-08-05Jun 2026$2.72
2026-05-07Mar 2026$1.96
2026-02-18Dec 2025$2.33
2025-11-05Sep 2025$2.32
2025-08-06Jun 2025$2.50
2025-05-07Mar 2025$2.06
2025-02-19Dec 2024$2.50

Filings and sources

Company website
criver.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

ICON plc (ICLR) · Revvity, Inc. (RVTY) · Medpace Holdings, Inc. (MEDP) · Labcorp Holdings Inc. (LH) · Quest Diagnostics Inc (DGX) · Mettler-Toledo International Inc (MTD) · Illumina, Inc. (ILMN) · Waters Corp (WAT)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades